Smith & Nephew (SNN) launched an INTERTAN Product Assurance (IPA) Program that will reimburse a healthcare facility for the cost of the TRIGEN™ INTERTAN™ Intertrochanteric Hip Fracture Nail if it fails to perform as expected.
The company estimates that hip fracture care has an annual cost of $12BB to $15BB to the healthcare system and an average reoperation rate of 6.6%. The IPA Program is intended to help mitigate this expense by potentially reducing the overall reoperation rate. Under the program, SNN will refund the cost of the implant to the facility for 12 months following the procedure.
Meta-analysis of data indicates that the implant, which uses a proprietary Integrated Compression Screw, outperformed other intertrochanteric nails using a traditional single screw. Results show that INTERTAN significantly reduced the risk of implant related failures by 81% and revision by 65% vs. single-screw nails.
"We feel that TRIGEN INTERTAN is the best hip fracture nail on the market, and we're willing to back that up with a program that underscores our confidence," said Craig Gaffin, Vice President and General Manager for Trauma and Extremities at Smith+Nephew. "The clinical evidence supporting its efficacy is overwhelming. Better patient outcomes mean better outcomes for hospitals, and we are thrilled to pass along these savings to the US healthcare system."
Source: Smith & Nephew